Delivery Order SPE2DB20D3111-SPE2DB23FA9YY
Award Date 9/11/23
Potential Completion Date 9/12/23
Potential Value $1.2K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $13,473.44 to Amerisourcebergen Drug Corporation for the supply of 4561889616 RESTASIS 0.05% eye emulsion in 60 single-use containers. Amerisourcebergen Drug Corporation will perform as the prime contractor, with corporate oversight provided by its parent company, Amerisourcebergen Corporation. Performance will take place in Conshohocken, Pennsylvania over a one-day period from August 21 to August 22, 2023. The...
- The Defense Logistics Agency awarded a $63,391 firm fixed price delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The order is for 30 units of the product, which will be delivered from Amerisourcebergen's facility in Conshohocken, Pennsylvania by August 25, 2023 to support the Defense Logistics Agency's medical supply needs. Amerisourcebergen will serve as the prime contractor on the order, which was issued under an existing DLA-wide supply contract vehicle...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at $1,800.80 to Amerisourcebergen Drug Corporation for the supply of 30 units of 0.05% RESTASIS eye emulsion. The place of performance will be Amerisourcebergen's Conshohocken, Pennsylvania facility from August 22 to August 23, 2023. As a major provider of pharmaceuticals and medical supplies to the Department of Defense, this order for a specific eye medication supports DLA's mission to provide logistics support for...
- The Defense Logistics Agency awarded a $16,586 delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. As the prime contractor, Amerisourcebergen will supply 60 units of the ophthalmic solution to support DLA programs. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania under a firm fixed price contract spanning August 18 through 21, 2023. No subcontractors or set aside designations were identified. DLA manages the global supply...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $2,173 to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The delivery order was issued under an indefinite-delivery/indefinite-quantity contract vehicle to supply pharmaceutical products and services to DLA customers. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania with delivery required by September 15, 2023. As a major provider of medical...
- The Defense Logistics Agency awarded a $7,368.09 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 60 units of 0.05% RESTASIS eye emulsion. The place of performance is Amerisourcebergen's Conshohocken, Pennsylvania facility. The order is scheduled to be completed between July 27-28, 2023. As a major supplier of pharmaceuticals and medical supplies to the Department of Defense, this order for eye medication supports the DLA's mission to provide logistics...
- The Defense Logistics Agency awarded a $540 firm fixed price delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. As the prime contractor, Amerisourcebergen will supply 30 units of the ophthalmic solution to support DLA's medical logistics programs. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a three day period in early July 2023. The delivery order was issued under DLA's pharmaceuticals and medical/surgical supply...
- The Defense Logistics Agency awarded a $540,180 firm fixed price delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The single award was issued against an unidentified indefinite-delivery/indefinite-quantity contract vehicle to supply 60 units of the ophthalmic solution. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a one day period from August 17-18, 2023. As a major distributor of pharmaceuticals and medical...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,080 to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The delivery order was issued against an unidentified contract vehicle to supply 30 units of the specified pharmaceutical product. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a period of one day, from June 20th through June 21st, 2023. No set aside designation or subcontractors...
- The Defense Logistics Agency awarded a $4,321 delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. As the prime contractor, Amerisourcebergen will supply 60 units of the product to the DLA under a firm fixed price contract. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a three-day period from July 7-10, 2023. No subcontractors or set aside designations were identified. The DLA manages the global supply chain for...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB23FA9YYDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at approximately $1,172 to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The order is to be performed in Conshohocken, Pennsylvania by Amerisourcebergen, a subsidiary of Amerisourcebergen Corporation, and provides 30 units of the ophthalmic solution to support DLA programs. No set-aside designation or subcontractors are indicated. The single day period of performance from September 11-12, 2023 suggests this micro-purchase supports near-term DLA medical supply needs.
Generated 12/18/23, 10:10 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/11/23 |